{"ticker": {"uuid": "bd1f2e80-d7b2-4154-9e21-3c958a3f5103", "symbol": "MESO", "name": "Mesoblast Ltd", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Mesoblast Limited (MESO) is a Great Momentum Stock: Should You Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxONTJCbTBJd2JNc2dQMjBjTTlYWV9Jdk5ydE5RZFVabXFkZDJxYTlzZ0hVTHVWd3lIU2kxdUVlX0ltWkgtOWpCYjZyUmEyWkNmRkZfdzlSeGY4dTlUUHNPWWxGN1c2WkJkZTFJQS1hQjN2WVBsdEMyZ3lFSmhDX1d6anJ2bVItNFpFME9KV0llQk1kc3hMUGQtZWV2VmFfamJjUE9CMQ?oc=5", "source_name": "Market source", "published_at": "2026-07-17T16:00:04+00:00", "published_display": "17 Jul 2026 16:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Mesoblast Limited (MESO) sees 278,571 director options lapse in July", "summary": "Mesoblast Limited (MESO) filed a Form 6-K reporting that 278,571 options belonging to Dr. Silviu Itescu, CEO and Executive Director, lapsed on July 7, 2026. This lapse was due to a previously achieved duplicative milestone, and no consideration was exchanged. Dr. Itescu's total o", "url": "https://www.stocktitan.net/sec-filings/MESO/6-k-mesoblast-ltd-current-report-foreign-issuer-55fcab22993e.html", "source_name": "Stock Titan", "published_at": "2026-07-15T10:11:27", "published_display": "15 Jul 2026 10:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (NASDAQ: MESO) reaches 300 patients in Phase 3 CLBP trial", "summary": "Mesoblast Limited announced it has enrolled 300 patients in its pivotal Phase 3 trial (MSB-DR004) for chronic low back pain associated with degenerative disc disease, meeting its target for a well-powered study. The trial aims to confirm the durable pain reduction seen previously", "url": "https://www.stocktitan.net/sec-filings/MESO/6-k-mesoblast-ltd-current-report-foreign-issuer-ca13f91b5391.html", "source_name": "Stock Titan", "published_at": "2026-07-14T12:11:13", "published_display": "14 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast Completes Treatment Target in Phase 3 Back Pain Trial", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/mesoblast-completes-treatment-target-phase-081718693.html", "source_name": "MT Newswires", "published_at": "2026-07-14T08:17:18+00:00", "published_display": "14 Jul 2026 08:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast reaches 300-patient Phase 3 trial target", "summary": "Mesoblast has successfully enrolled 300 patients in its Phase 3 clinical trial for rexlemestrocel-L, a therapy targeting chronic low back pain. The company anticipates releasing top-line results by mid-2027 and believes the treatment has the potential to generate over $10 billion", "url": "https://grafa.com/en/news/united-states/mesoblast-300-patient-phase-3-back-pain-trial", "source_name": "grafa.com", "published_at": "2026-07-14T08:51:00", "published_display": "14 Jul 2026 08:51", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Mesoblast (ASX:MSB) Trading Within Its 52-Week Price Range?", "summary": "Mesoblast (ASX:MSB) shares declined by 0.21% to AUD 2.345 during the latest trading session, with trading volumes below average. The stock's intraday range was AUD 2.285 to AUD 2.380, and it has a market capitalization of AUD 2.89 billion. Mesoblast continues to trade within its ", "url": "https://kalkine.com.au/news/healthcare/is-mesoblast-asxmsb-trading-within-its-52-week-price-range", "source_name": "Kalkine", "published_at": "2026-07-14T05:42:08", "published_display": "14 Jul 2026 05:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Australia's Mesoblast reaches target of 300 trial patients", "summary": "Australian biotechnology company Mesoblast has successfully enrolled 300 patients in its pivotal Phase 3 trial for chronic low back pain. This milestone, which led to a rise in the company's share price, is crucial for validating its new therapy and supporting future regulatory a", "url": "https://grafa.com/en/news/australia/mesoblast-reaches-target-of-300-trial-patients", "source_name": "grafa.com", "published_at": "2026-07-14T02:27:00", "published_display": "14 Jul 2026 02:27", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast reaches 300-patient enrollment in back pain trial By Investing.com", "summary": "Mesoblast Limited has successfully enrolled over 300 patients in its Phase 3 trial for chronic low back pain using rexlemestrocel-L, a significant milestone that led to a 13% stock increase. The trial, designed in agreement with the FDA, aims to measure pain reduction and other i", "url": "https://za.investing.com/news/stock-market-news/mesoblast-reaches-300patient-enrollment-in-back-pain-trial-93CH-4367158", "source_name": "Investing.com South Africa", "published_at": "2026-07-14T01:42:08", "published_display": "14 Jul 2026 01:42", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast Tests One Injection for Chronic Low Back Pain", "summary": "Mesoblast (Nasdaq: MESO; ASX: MSB) announced it has reached its target of 300 treated patients in its pivotal Phase 3 trial (MSB-DR004) for chronic low back pain (CLBP) associated with degenerative disc disease. The trial, utilizing rexlemestrocel-L, aims to confirm durable pain ", "url": "https://www.stocktitan.net/news/MESO/mesoblast-achieves-target-of-300-treated-patients-in-pivotal-phase-3-kmthdkws6ysa.html", "source_name": "Stock Titan", "published_at": "2026-07-14T00:42:08", "published_display": "14 Jul 2026 00:42", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain", "summary": "Mesoblast Limited announced it has achieved its target of treating 300 patients in its pivotal Phase 3 trial (MSB-DR004) for chronic low back pain (CLBP) associated with degenerative disc disease. The trial aims to confirm durable pain reduction using rexlemestrocel-L, building o", "url": "https://sg.finance.yahoo.com/news/mesoblast-achieves-target-300-treated-003500335.html", "source_name": "Market source", "published_at": "2026-07-13T22:35:00", "published_display": "13 Jul 2026 22:35", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (MESO) Reports Strong Revenue Growth for Ryoncil", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNRHhfWnZNU0JSUDY5cXpNazhGUy1pYm50bVYyVzZ2R1djclB6YTRRclBXVkczTHhmakE2WkIzV2ExX01UaXhBN3piWjZHa1ctcnFTcFNER3p2ZmlQS3JhM3NtcThGeVhwUGZCc3Z0Sk5YM1ZkUW9JMTd1b1JyNHU0U25aM0hCaUNOWUJGS2tjNVdoZFR1VjNtcVRtSWpJSG9KZ1RzYldRTHBFdWM?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-13T19:58:09+00:00", "published_display": "13 Jul 2026 19:58", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (MESO) Sees 6.2% Increase in Share Value", "summary": "Mesoblast (MESO) saw a 6.2% increase in its share value, reaching $16.40, driven by growing investor confidence in its allogeneic cellular medicines for severe inflammatory conditions. Despite positive investor sentiment and insider buys, the company\u2019s valuation metrics, includin", "url": "https://www.gurufocus.com/news/8955627/mesoblast-meso-sees-62-increase-in-share-value", "source_name": "GuruFocus", "published_at": "2026-07-13T14:40:15", "published_display": "13 Jul 2026 14:40", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Australia shares higher at close of trade; S&P/ASX 200 up 0.03%", "summary": "Australian shares concluded Monday's trading session higher, with the S&P/ASX 200 index rising by 0.03%. Gains were primarily driven by the Telecoms Services, Consumer Discretionary, and Financials sectors. Notable gainers included Mesoblast Ltd, Stanmore Coal, and Ampol Ltd, whi", "url": "https://m.uk.investing.com/news/stock-market-news/australia-shares-higher-at-close-of-trade-spasx-200-up-003-4766798?ampMode=1", "source_name": "Investing.com", "published_at": "2026-07-13T06:40:15", "published_display": "13 Jul 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast Jumps 7% (ASX:MSB): Is Fresh Momentum Building Around This ASX Biotech Stock?", "summary": "Mesoblast Limited (ASX: MSB) experienced a notable 7.14% surge on July 13, 2026, reaching $2.40, amidst a declining broader Health Care sector. This gain occurred without any immediate company-specific announcement, shortly after Mesoblast reported US$115 million in Ryoncil net r", "url": "https://kalkine.com.au/news/healthcare/mesoblast-jumps-7-asxmsb-is-fresh-momentum-building-around-this-asx-biotech-stock", "source_name": "Kalkine", "published_at": "2026-07-13T04:11:38", "published_display": "13 Jul 2026 04:11", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Mesoblast's US Heart Therapy Filing Entering Its Defining Phase?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPZ1N2MjhTQlJneGM2TjRJWEZTYk5vbU9JeUprRW11YVhCZkZpLTNhTFJ2YVpOZXpWeGlITi1aYzhOSmNWZGdCTzJ5c3o5SGN4dXdrRlMzRm5VOFlnVExuMm9LZzdVZHFrUzZHLXFtQXRRazlPanRaY19FMkIzbF9EWS1YQ3NNd1NVczRZNXVTcnkyY3FrRk10Qk1oTmx5RVJQR3RoMnVVbGk5MWc?oc=5", "source_name": "Kalkine Media", "published_at": "2026-07-13T03:08:00+00:00", "published_display": "13 Jul 2026 03:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast Moved to Buy From Speculative Buy by Bell Potter", "summary": "Bell Potter has upgraded Mesoblast (ASX:MSB) from a \"Speculative Buy\" to a \"Buy\" rating, reflecting increased confidence in the company. This upgrade suggests a more positive outlook from the analyst firm regarding Mesoblast's potential.", "url": "https://www.moomoo.com/news/post/72814676/mesoblast-moved-to-buy-from-speculative-buy-by-bell-potter?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-13T02:40:15", "published_display": "13 Jul 2026 02:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (ASX:MSB) Is Up 8.7% After Strong Ryoncil Debut And FDA BLA Milestone - Has The Bull Case Changed?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-12T00:33:02+00:00", "published_display": "12 Jul 2026 00:33", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast: The Commercial Proof Is Now Becoming The Investment Thesis (NASDAQ:MESO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOSDVlQ01vWVgxdGFnUmlwSjZsbG1LUkVkY2dZdlNZZmN2REZOa2YyNmVjOTNEYlYxLXhsMzlRczNBSUd1NzRkbGNuRTN5dTdsUXB3UlRaR3Ywam85MlJDSmE2endESlNKTnVZVGc2S2toOWt0cUM1d2xOemYtcjNYZUhXaDhkbEE1a3k5amlqb0cxSWtQclhWWUxCbVVLOU9HMGw4QTlFTEJQNjNCamc?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-11T11:59:12+00:00", "published_display": "11 Jul 2026 11:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast reports $115 million Ryoncil revenue in FY2026", "summary": "Mesoblast reported preliminary Ryoncil revenue of US$115 million for the full fiscal year ended June 30, 2026, exceeding initial projections. The company recorded US$36 million in revenue for the fourth quarter and anticipates continued growth in fiscal 2027 as adoption expands a", "url": "https://grafa.com/en/news/united-states/mesoblast-ryoncil-revenue-reaches-115-million-fy2026", "source_name": "grafa.com", "published_at": "2026-07-10T12:10:28", "published_display": "10 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 91, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (MESO) reports US$115M first full-year Ryoncil sales and strong Q4", "summary": "Mesoblast (MESO) reported preliminary net revenue of US$36 million for Ryoncil\u00ae in the fourth quarter and US$115 million for its first full commercial year ending June 30, 2026. This exceeds initial projections, with strong uptake in major U.S. pediatric centers. The company also", "url": "https://www.stocktitan.net/sec-filings/MESO/6-k-mesoblast-ltd-current-report-foreign-issuer-12316f163b23.html", "source_name": "Stock Titan", "published_at": "2026-07-10T09:39:36", "published_display": "10 Jul 2026 09:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast Reports $36 Million Ryoncil Revenue for Fiscal Q4", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/mesoblast-reports-36-million-ryoncil-074054991.html", "source_name": "MT Newswires", "published_at": "2026-07-10T07:40:54+00:00", "published_display": "10 Jul 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Degenerative Disc Disease Market Statistics Expected to Experience Major Growth by 2036, According to DelveInsight | Mesoblast, DiscGenics, Biosplice Therapeutics, BIOPHARM GmbH, Yuhan, Histogen", "summary": "The global Degenerative Disc Disease (DDD) market is projected to experience substantial growth, increasing from approximately USD 1.2 billion in 2025 to nearly USD 7.2 billion by 2036, with a CAGR of 19.04%. This expansion is attributed to advancements in regenerative therapies,", "url": "https://www.barchart.com/story/news/3206658/degenerative-disc-disease-market-statistics-expected-to-experience-major-growth-by-2036-according-to-delveinsight-mesoblast-discgenics-biosplice-therapeutics-biopharm-gmbh-yuhan-histogen", "source_name": "Barchart.com", "published_at": "2026-07-10T07:42:08", "published_display": "10 Jul 2026 07:42", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (MESO) CFO awarded 650,000 options at A$2.90 strike, expiring 2032", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPZ0JLNEx4OGRnM1NPbFRGMkxvMWEydk5QQ0JCNmNKd3RrVk5sRWxuNE5Pb0xaaHNQVTNBS2xMejRSZmUtdFJ2RFE4cTNxTkZDZ0NSNXhNUkdQWEtjR21XalRIcThibXBfQ1hhMDBqakRTZVMxMFdtUkYwWnZCellRMHJOQ2NZdVVnNm1zU2RkUURpUEpxazc5OVpSQ1pFVkhnTmJELWd1MklCUWc?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-10T02:10:18+00:00", "published_display": "10 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ryoncil revenue hits US$36M in Q4, FY26 total at US$115M", "summary": "Mesoblast Limited announced strong Ryoncil net revenue, reaching US$36 million in Q4 FY26 and US$115 million for the full fiscal year, exceeding projections due to high U.S. pediatric demand. CEO Dr. Silviu Itescu confirmed the company's robust capital position, fueled by revenue", "url": "https://scanx.trade/stock-market-news/companies/ryoncil-revenue-hits-us-36m-in-q4-fy26-total-at-us-115m/45191341", "source_name": "scanx.trade", "published_at": "2026-07-10T03:10:17", "published_display": "10 Jul 2026 03:10", "sentiment": "positive", "sentiment_pct": 93, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast delivers full year revenue of US$115M", "summary": "Mesoblast (ASX:MSB) reported a full-year net revenue of US$115 million, exceeding initial projections due to strong sales of its approved cellular medicine. The company also recorded US$36 million in net revenue for the fourth quarter and plans to use a new five-year credit facil", "url": "https://grafa.com/en/news/australia/mesoblast-delivers-full-year-revenue-of-us-115m", "source_name": "grafa.com", "published_at": "2026-07-10T01:01:00", "published_display": "10 Jul 2026 01:01", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast Reports Strong RYONCIL\u00ae Revenue, Exceeding Projections", "summary": "Mesoblast Limited (ASX:MSB) announced strong financial results for its product Ryoncil\u00ae, with Q4 net revenue of US$36 million and a full-year net revenue of US$115 million, exceeding initial projections. Ryoncil\u00ae is the first FDA-approved mesenchymal stromal cell product for chil", "url": "https://www.sharecafe.com.au/2026/07/10/mesoblast-reports-strong-ryoncil-revenue-exceeding-projections/", "source_name": "Sharecafe", "published_at": "2026-07-10T00:10:17", "published_display": "10 Jul 2026 00:10", "sentiment": "positive", "sentiment_pct": 93, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ryoncil\u00ae Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026", "summary": "Mesoblast Limited announced Ryoncil\u00ae (remestemcel-L-rknd) achieved net revenue of US$36 million for the fourth quarter and US$115 million for the full year ended June 30, 2026. The company is pleased with Ryoncil's market uptake since its launch and anticipates continued revenue ", "url": "https://sg.finance.yahoo.com/news/ryoncil-delivers-net-revenue-us-003000076.html", "source_name": "Market source", "published_at": "2026-07-09T20:30:00", "published_display": "09 Jul 2026 20:30", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast Ltd outlook for regenerative medicine. MESO stock aligns long-term strategy", "summary": "Mesoblast Ltd is a biotechnology company focused on developing regenerative cell therapies for serious inflammatory and cardiovascular diseases, with its MESO stock reflecting a long-term investment case in advanced biologics. The company's strategy involves a pipeline of allogen", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/mesoblast-ltd-outlook-for-regenerative-medicine-meso-stock-aligns/69716898", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T19:09:23", "published_display": "07 Jul 2026 19:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Mesoblast (ASX:MSB) Is Up 9.3% After FDA Accepts Modular BLA Review For Rexlemestrocel-L", "summary": "Mesoblast (ASX:MSB) shares rose 9.3% after the FDA accepted a modular Biologics License Application (BLA) review for its drug rexlemestrocel-L. The drug aims to prevent life-threatening gastrointestinal bleeding in end-stage heart failure patients supported by left ventricular as", "url": "https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/why-mesoblast-asxmsb-is-up-93-after-fda-accepts-modular-bla/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-03T17:10:32", "published_display": "03 Jul 2026 17:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bell Potter Maintains MESOBLAST LTD(MEOBF.US) With Buy Rating, Raises Target Price to $3.08", "summary": "Bell Potter has reiterated its Buy rating for MESOBLAST LTD (MEOBF.US) and increased its target price to $3.08. This suggests a continued positive outlook from the analyst firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/72360550/bell-potter-maintains-mesoblast-ltd-meobfus-with-buy-rating-raises", "source_name": "Moomoo", "published_at": "2026-07-02T05:40:27", "published_display": "02 Jul 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Mesoblast (ASX:MSB) Undervalued Following FDA Progress For Rexlemestrocel L?", "summary": "Mesoblast (ASX:MSB) stock is gaining attention after the US FDA accepted its Biologics License Application for rexlemestrocel-L and granted a modular review request for LVAD-related risks, streamlining its approval pathway. Despite recent gains, the stock remains down 26.35% year", "url": "https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-mesoblast-asxmsb-undervalued-following-fda-progress-for-r/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-02T05:40:16", "published_display": "02 Jul 2026 05:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (ASX:MSB) Stock Forecast & Analyst Predictions", "summary": "Mesoblast (ASX:MSB) is forecast to achieve significant earnings and revenue growth, with EPS expected to grow by 72.5% and revenue by 38.4% annually. The company has multiple products in development and commercialization, including Ryoncil (FDA-approved) and Rexlemestrocel-L, tar", "url": "https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/future", "source_name": "Simply Wall Street", "published_at": "2026-07-02T04:10:32", "published_display": "02 Jul 2026 04:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (NASDAQ: MESO) moves rexlemestrocel-L BLA into FDA modular review", "summary": "Mesoblast Limited (NASDAQ: MESO) announced it has received a Biologics License Application (BLA) filing number from the FDA for its cell therapy rexlemestrocel-L. The company has requested a modular review for the therapy, which aims to prevent life-threatening gastrointestinal b", "url": "https://www.stocktitan.net/sec-filings/MESO/6-k-mesoblast-ltd-current-report-foreign-issuer-f37ae55f07e4.html", "source_name": "Stock Titan", "published_at": "2026-07-01T09:39:11", "published_display": "01 Jul 2026 09:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs", "summary": "Mesoblast Limited has received a Biologics License Application (BLA) filing number from the U.S. FDA for rexlemestrocel-L and requested a modular review. This therapy aims to prevent life-threatening gastrointestinal bleeding in end-stage heart failure patients with LVADs, an ind", "url": "https://sg.finance.yahoo.com/news/mesoblast-receives-bla-filing-number-003800419.html", "source_name": "Market source", "published_at": "2026-07-01T03:40:55", "published_display": "01 Jul 2026 03:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Duratec (ASX:DUR), Elsight (ASX:ELS) and Mesoblast (ASX:MSB): Why These Growth Stocks Are Drawing Market Attention", "summary": "Duratec (ASX:DUR), Elsight (ASX:ELS), and Mesoblast (ASX:MSB) are attracting significant market attention due to their expanding growth opportunities, substantial insider ownership, and strong operational execution. These companies operate in diverse sectors including infrastruct", "url": "https://kalkinemedia.com/au/stocks/growth/duratec-asxdur-elsight-asxels-and-mesoblast-asxmsb-why-these-growth-stocks-are-drawing-market-attention", "source_name": "Kalkine Media", "published_at": "2026-07-01T01:09:34", "published_display": "01 Jul 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (MESO) Secures FDA Filing for Rexlemestrocel-L Review", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPTXNqRmM5bW5lRHR0bDl3MWFNYTBBWVR3V1l5VEw2dlBXT09VX0FkZ0JQaW9SNUU2cnJvMUJ2ci1OSkE4UHNfZE4ydDU2d3JLT0JkYWxXQVQyT1FhcE94dGJFMk5UZDJybmFkV0hOMGxCQmlBRkxXSlFBZnVVWXV3Z0Zub1VJUkRIdFFxZE1YcUUyamkwR3RRN2NkN1dBeGpwWVBacDNtNlVnQzBLOWN3SVBhSUFQRGMtZXdEODhqTWtDV3NpVlNOOFRuM3hua1NPRTVfOUtR?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast Accesses $50 Million Credit Line to Refinance Debt Obligations", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/mesoblast-accesses-50-million-credit-083916175.html", "source_name": "MT Newswires", "published_at": "2026-06-25T08:39:16+00:00", "published_display": "25 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Mesoblast Limited (MESO), One of the Best Long-Term ASX Stocks To Buy Right Now; See Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQSnM4Q1AzUmFfMkVIQ0xuNW9NY2lVQWwyV0FZc1BueEIyYUN0TzRDOTVHcUFnX2JpVG5oajhaUEVyXzcxRDllWGZGQlEyTmlRa0o0VFhpUklGNUVITjBCamkyZ0RwXzROVmh5bDdKVm8xTWViUXRQaTdfbHEwNndiME04eXFsdnNJa3hkRlhicC1fN3AyZWcyWVJsUmo?oc=5", "source_name": "Market source", "published_at": "2026-04-19T07:00:00+00:00", "published_display": "19 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Mesoblast Limited (MESO) is One of the Best Low Priced Biotech Stocks to Invest in", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNb2REazdfc0JsenFOLVJLMnNyNmx6R0tHU3JqTGlaYnF4LTVvNnNGTjRRYW83UzZqLUFxdG1feVRzQlBfLTRrcEsxS0N6X0lJcnlKaVh1ZFR2TS1yaU41U1AyeExfNnU5YUVDak1aMEUxbFcwcVlZUGhDMkZoVTVkajZyV3RsR25ha0NiU3c5V3VobHNPdGF3WXhGaWxRWjRH?oc=5", "source_name": "Market source", "published_at": "2026-04-19T07:00:00+00:00", "published_display": "19 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gregory George Adds To Mesoblast Position With Multi-Market Share Purchases", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOZ0JKWk93LVJ6YnNrVHY1UThpQktrN2R6X0ZIT2l0Zlo2LVJTcVZfUHYtNjZxVmYxRmtxZkJQcnFmM21XeGwtRjFYLW16QzFmVGxBb00tVzM3RUVtV1ZXeWdCc0NUUnJ2T3JWbmQySi1MMERhTlFOaDJXQ3hITldxM3V1NTlnbHRIc0s2eXdJNnY4RFJjNmt3?oc=5", "source_name": "Market source", "published_at": "2026-04-12T07:00:00+00:00", "published_display": "12 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast says Ryoncil is nearing $100M as new trials move ahead", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQbzZoSFRVQXM3OHUyN2RqSHlMZUlFS2NWRDJ5R2hyT3JTUC1RaEVtVlAxVmprYS1qck5GUlBNWEZwLUNiVWNLT0NJVmFrc1NBOGNaanRSSzJLaWxCb2RvR3hwaTlRdDFKOVltRWE2QjFlbVlKb2hyRGxCTWdiMGw1ckNCRVgyb1B2RmtINlQtRVJJU3lJOWxPdEl5U294ai1xc0g1OWJPNU83azNLQW9PYTNKY0NuVU9HMDY4b19Ucw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Mesoblast (ASX:MSB) Offering Value After Recent Share Price Declines?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast shares are back in the red on Tuesday. Here\u2019s why", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNYlZMMG9CbC1Qei1paGlEaUNnWC1YUFdZeDJ1dG5EMW1sQXBJQllBZkVxaklNZU9mWjVFcXpSYlhlLVRPd3ZxdzNMY3NiNE8yZEVWeHJ3cWNfanZRWDJSWENtNU9lenUwa3JqSUhPdUNIb3J5LXlLdE9ZQ1FCVi10MHA2YTV1X3NFZGd1SzRWZEdrTW1sc2s3UA?oc=5", "source_name": "The Motley Fool Australia", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (ASX:MSB; Nasdaq:MESO) Sets Stage for R&D Day as Ryoncil\u00ae Gains Commercial Traction", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPOWdlbWxiX2dUbXBrRF9YakpoZ1dLX1F0eGFaTjU5LVVPSnVuWkU0cmptcUo2RUE4a1k0dFJfRlVoZ29RYktYRk1OcXpoSHhMbURxQjNuVUdxc2tSZnd3eEVUNGQyY1VlTkhyWDJEM0FzcHlLNVFKWl90MDF6Y004Z19KQWxCcHgwLU5Ob1RxeFZzc0FCRzlxRmVlMWtaV2hROGQyY2h5OHRfalNGVmZOV3cxTnRPc0ZsX0h2TTU5VlBndlN1OUp4Z2RRTmg?oc=5", "source_name": "Kalkine Media", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast to spotlight multi-billion pipeline at April 8 R&D Day", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPeW1KNnFnV2EzV3RXZThjTGdyVkFMQVVnQzhOY3BRUnktRkR6VFpjY3ZiSUxnSmlnNE1YdVNJQTFCYno0RG9NY3ktMGVNMllEOUZsYXR1dXhHM1NheVZyVkhlYjRjLThGbENaOUxiaXoxVzZrUFJvMXNuQVBOSm11NkdMVk9zVjFRWnFTUUVXMDQwRzJLS2c?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (ASX:MSB) Is Down 7.1% After Issuing First Ryoncil 2026 Revenue Guidance \u2013 Has The Bull Case Changed?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiekFVX3lxTE56ZjVJaVI3VG9rT1F0SmZvTzZvX2ZLTVpWOFJhN3BvbkVsZEsxNm1oa1lhSHZKWDFWU3kyWEthSzhkbE9UMmZoaGdoY0NkQXZ0WGNqQlNQT3RwYkVUVjJ6cTgtWGpNdHdhTEJOTjVWSVRmLXBQQXQ4OTF3?oc=5", "source_name": "Market source", "published_at": "2026-02-28T08:00:00+00:00", "published_display": "28 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast H1 2026 Loss Of US$94.4 Million Tests Bullish Profitability Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-28T08:00:00+00:00", "published_display": "28 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ryoncil drives Mesoblast (NASDAQ: MESO) H1 FY2026 growth and FY26 guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNV3FXQkpNNHhmdEttbTdZYVhPek45Q25GNUZCNk1NdGYxWjdCdlFuY3hucjZiRGhPSm5EZUV0Z0ZXUldPSGpPeWxhN0Y3UmU0NDBCR3JPWGRBS28zeWRvNXFZcGJ0SEdwMnBDbkVGMUgwX3JYUm1HaGNfNXE3a3hUdG93RTFyc25nSXhqeXpWWGF0MlpqTzBadERNbENIb0dmWm96OTJpb2F3THJRaXc?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast Limited (MESO) Stock Analysis: Exploring A 109.83% Potential Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPNlRqcTlzYTE0OXFvaFcyYVZyUEVqYWFKRXRvUm84Rm8xZ1BXRFhUUjBjWWpVZ1FjekdOZHlKUUxBaXUybHNYMTI3YXJIY1pCcHJTbm9MUV9zTThwekNuOExJcGh5SnBZcjY3TVY2TGg0Z0NnWVlKY1JPdHQxTDR6S2RQT0VBNFBsTmlXX29nLTA1MEhtbVMxV3NMU1E3a3FEdWdmdWpUN1Jkcmt5d2w2Rl9POUxOa3VWMEV0c00yUG1zQQ?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast Limited (ASX:MSB) Consensus Forecasts Have Become A Little Darker Since Its Latest Report", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-01T07:00:00+00:00", "published_display": "01 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insiders were the key beneficiaries as Mesoblast Limited's (ASX:MSB) market cap rises to AU$3.0b", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-20T07:00:00+00:00", "published_display": "20 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Mesoblast Limited (MESO) is a Great Momentum Stock: Should You Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxONTJCbTBJd2JNc2dQMjBjTTlYWV9Jdk5ydE5RZFVabXFkZDJxYTlzZ0hVTHVWd3lIU2kxdUVlX0ltWkgtOWpCYjZyUmEyWkNmRkZfdzlSeGY4dTlUUHNPWWxGN1c2WkJkZTFJQS1hQjN2WVBsdEMyZ3lFSmhDX1d6anJ2bVItNFpFME9KV0llQk1kc3hMUGQtZWV2VmFfamJjUE9CMQ?oc=5", "source_name": "Market source", "published_at": "2026-07-17T16:00:04+00:00", "published_display": "17 Jul 2026 16:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast Limited (MESO) sees 278,571 director options lapse in July", "summary": "Mesoblast Limited (MESO) filed a Form 6-K reporting that 278,571 options belonging to Dr. Silviu Itescu, CEO and Executive Director, lapsed on July 7, 2026. This lapse was due to a previously achieved duplicative milestone, and no consideration was exchanged. Dr. Itescu's total o", "url": "https://www.stocktitan.net/sec-filings/MESO/6-k-mesoblast-ltd-current-report-foreign-issuer-55fcab22993e.html", "source_name": "Stock Titan", "published_at": "2026-07-15T10:11:27", "published_display": "15 Jul 2026 10:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (NASDAQ: MESO) reaches 300 patients in Phase 3 CLBP trial", "summary": "Mesoblast Limited announced it has enrolled 300 patients in its pivotal Phase 3 trial (MSB-DR004) for chronic low back pain associated with degenerative disc disease, meeting its target for a well-powered study. The trial aims to confirm the durable pain reduction seen previously", "url": "https://www.stocktitan.net/sec-filings/MESO/6-k-mesoblast-ltd-current-report-foreign-issuer-ca13f91b5391.html", "source_name": "Stock Titan", "published_at": "2026-07-14T12:11:13", "published_display": "14 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast Completes Treatment Target in Phase 3 Back Pain Trial", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/mesoblast-completes-treatment-target-phase-081718693.html", "source_name": "MT Newswires", "published_at": "2026-07-14T08:17:18+00:00", "published_display": "14 Jul 2026 08:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast reaches 300-patient Phase 3 trial target", "summary": "Mesoblast has successfully enrolled 300 patients in its Phase 3 clinical trial for rexlemestrocel-L, a therapy targeting chronic low back pain. The company anticipates releasing top-line results by mid-2027 and believes the treatment has the potential to generate over $10 billion", "url": "https://grafa.com/en/news/united-states/mesoblast-300-patient-phase-3-back-pain-trial", "source_name": "grafa.com", "published_at": "2026-07-14T08:51:00", "published_display": "14 Jul 2026 08:51", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Mesoblast (ASX:MSB) Trading Within Its 52-Week Price Range?", "summary": "Mesoblast (ASX:MSB) shares declined by 0.21% to AUD 2.345 during the latest trading session, with trading volumes below average. The stock's intraday range was AUD 2.285 to AUD 2.380, and it has a market capitalization of AUD 2.89 billion. Mesoblast continues to trade within its ", "url": "https://kalkine.com.au/news/healthcare/is-mesoblast-asxmsb-trading-within-its-52-week-price-range", "source_name": "Kalkine", "published_at": "2026-07-14T05:42:08", "published_display": "14 Jul 2026 05:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Australia's Mesoblast reaches target of 300 trial patients", "summary": "Australian biotechnology company Mesoblast has successfully enrolled 300 patients in its pivotal Phase 3 trial for chronic low back pain. This milestone, which led to a rise in the company's share price, is crucial for validating its new therapy and supporting future regulatory a", "url": "https://grafa.com/en/news/australia/mesoblast-reaches-target-of-300-trial-patients", "source_name": "grafa.com", "published_at": "2026-07-14T02:27:00", "published_display": "14 Jul 2026 02:27", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast reaches 300-patient enrollment in back pain trial By Investing.com", "summary": "Mesoblast Limited has successfully enrolled over 300 patients in its Phase 3 trial for chronic low back pain using rexlemestrocel-L, a significant milestone that led to a 13% stock increase. The trial, designed in agreement with the FDA, aims to measure pain reduction and other i", "url": "https://za.investing.com/news/stock-market-news/mesoblast-reaches-300patient-enrollment-in-back-pain-trial-93CH-4367158", "source_name": "Investing.com South Africa", "published_at": "2026-07-14T01:42:08", "published_display": "14 Jul 2026 01:42", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast Tests One Injection for Chronic Low Back Pain", "summary": "Mesoblast (Nasdaq: MESO; ASX: MSB) announced it has reached its target of 300 treated patients in its pivotal Phase 3 trial (MSB-DR004) for chronic low back pain (CLBP) associated with degenerative disc disease. The trial, utilizing rexlemestrocel-L, aims to confirm durable pain ", "url": "https://www.stocktitan.net/news/MESO/mesoblast-achieves-target-of-300-treated-patients-in-pivotal-phase-3-kmthdkws6ysa.html", "source_name": "Stock Titan", "published_at": "2026-07-14T00:42:08", "published_display": "14 Jul 2026 00:42", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain", "summary": "Mesoblast Limited announced it has achieved its target of treating 300 patients in its pivotal Phase 3 trial (MSB-DR004) for chronic low back pain (CLBP) associated with degenerative disc disease. The trial aims to confirm durable pain reduction using rexlemestrocel-L, building o", "url": "https://sg.finance.yahoo.com/news/mesoblast-achieves-target-300-treated-003500335.html", "source_name": "Market source", "published_at": "2026-07-13T22:35:00", "published_display": "13 Jul 2026 22:35", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (MESO) Reports Strong Revenue Growth for Ryoncil", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxNRHhfWnZNU0JSUDY5cXpNazhGUy1pYm50bVYyVzZ2R1djclB6YTRRclBXVkczTHhmakE2WkIzV2ExX01UaXhBN3piWjZHa1ctcnFTcFNER3p2ZmlQS3JhM3NtcThGeVhwUGZCc3Z0Sk5YM1ZkUW9JMTd1b1JyNHU0U25aM0hCaUNOWUJGS2tjNVdoZFR1VjNtcVRtSWpJSG9KZ1RzYldRTHBFdWM?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-13T19:58:09+00:00", "published_display": "13 Jul 2026 19:58", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (MESO) Sees 6.2% Increase in Share Value", "summary": "Mesoblast (MESO) saw a 6.2% increase in its share value, reaching $16.40, driven by growing investor confidence in its allogeneic cellular medicines for severe inflammatory conditions. Despite positive investor sentiment and insider buys, the company\u2019s valuation metrics, includin", "url": "https://www.gurufocus.com/news/8955627/mesoblast-meso-sees-62-increase-in-share-value", "source_name": "GuruFocus", "published_at": "2026-07-13T14:40:15", "published_display": "13 Jul 2026 14:40", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Australia shares higher at close of trade; S&P/ASX 200 up 0.03%", "summary": "Australian shares concluded Monday's trading session higher, with the S&P/ASX 200 index rising by 0.03%. Gains were primarily driven by the Telecoms Services, Consumer Discretionary, and Financials sectors. Notable gainers included Mesoblast Ltd, Stanmore Coal, and Ampol Ltd, whi", "url": "https://m.uk.investing.com/news/stock-market-news/australia-shares-higher-at-close-of-trade-spasx-200-up-003-4766798?ampMode=1", "source_name": "Investing.com", "published_at": "2026-07-13T06:40:15", "published_display": "13 Jul 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast Jumps 7% (ASX:MSB): Is Fresh Momentum Building Around This ASX Biotech Stock?", "summary": "Mesoblast Limited (ASX: MSB) experienced a notable 7.14% surge on July 13, 2026, reaching $2.40, amidst a declining broader Health Care sector. This gain occurred without any immediate company-specific announcement, shortly after Mesoblast reported US$115 million in Ryoncil net r", "url": "https://kalkine.com.au/news/healthcare/mesoblast-jumps-7-asxmsb-is-fresh-momentum-building-around-this-asx-biotech-stock", "source_name": "Kalkine", "published_at": "2026-07-13T04:11:38", "published_display": "13 Jul 2026 04:11", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Mesoblast's US Heart Therapy Filing Entering Its Defining Phase?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPZ1N2MjhTQlJneGM2TjRJWEZTYk5vbU9JeUprRW11YVhCZkZpLTNhTFJ2YVpOZXpWeGlITi1aYzhOSmNWZGdCTzJ5c3o5SGN4dXdrRlMzRm5VOFlnVExuMm9LZzdVZHFrUzZHLXFtQXRRazlPanRaY19FMkIzbF9EWS1YQ3NNd1NVczRZNXVTcnkyY3FrRk10Qk1oTmx5RVJQR3RoMnVVbGk5MWc?oc=5", "source_name": "Kalkine Media", "published_at": "2026-07-13T03:08:00+00:00", "published_display": "13 Jul 2026 03:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast Moved to Buy From Speculative Buy by Bell Potter", "summary": "Bell Potter has upgraded Mesoblast (ASX:MSB) from a \"Speculative Buy\" to a \"Buy\" rating, reflecting increased confidence in the company. This upgrade suggests a more positive outlook from the analyst firm regarding Mesoblast's potential.", "url": "https://www.moomoo.com/news/post/72814676/mesoblast-moved-to-buy-from-speculative-buy-by-bell-potter?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-13T02:40:15", "published_display": "13 Jul 2026 02:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (ASX:MSB) Is Up 8.7% After Strong Ryoncil Debut And FDA BLA Milestone - Has The Bull Case Changed?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-12T00:33:02+00:00", "published_display": "12 Jul 2026 00:33", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast: The Commercial Proof Is Now Becoming The Investment Thesis (NASDAQ:MESO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOSDVlQ01vWVgxdGFnUmlwSjZsbG1LUkVkY2dZdlNZZmN2REZOa2YyNmVjOTNEYlYxLXhsMzlRczNBSUd1NzRkbGNuRTN5dTdsUXB3UlRaR3Ywam85MlJDSmE2endESlNKTnVZVGc2S2toOWt0cUM1d2xOemYtcjNYZUhXaDhkbEE1a3k5amlqb0cxSWtQclhWWUxCbVVLOU9HMGw4QTlFTEJQNjNCamc?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-11T11:59:12+00:00", "published_display": "11 Jul 2026 11:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast reports $115 million Ryoncil revenue in FY2026", "summary": "Mesoblast reported preliminary Ryoncil revenue of US$115 million for the full fiscal year ended June 30, 2026, exceeding initial projections. The company recorded US$36 million in revenue for the fourth quarter and anticipates continued growth in fiscal 2027 as adoption expands a", "url": "https://grafa.com/en/news/united-states/mesoblast-ryoncil-revenue-reaches-115-million-fy2026", "source_name": "grafa.com", "published_at": "2026-07-10T12:10:28", "published_display": "10 Jul 2026 12:10", "sentiment": "positive", "sentiment_pct": 91, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (MESO) reports US$115M first full-year Ryoncil sales and strong Q4", "summary": "Mesoblast (MESO) reported preliminary net revenue of US$36 million for Ryoncil\u00ae in the fourth quarter and US$115 million for its first full commercial year ending June 30, 2026. This exceeds initial projections, with strong uptake in major U.S. pediatric centers. The company also", "url": "https://www.stocktitan.net/sec-filings/MESO/6-k-mesoblast-ltd-current-report-foreign-issuer-12316f163b23.html", "source_name": "Stock Titan", "published_at": "2026-07-10T09:39:36", "published_display": "10 Jul 2026 09:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast Reports $36 Million Ryoncil Revenue for Fiscal Q4", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/mesoblast-reports-36-million-ryoncil-074054991.html", "source_name": "MT Newswires", "published_at": "2026-07-10T07:40:54+00:00", "published_display": "10 Jul 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Degenerative Disc Disease Market Statistics Expected to Experience Major Growth by 2036, According to DelveInsight | Mesoblast, DiscGenics, Biosplice Therapeutics, BIOPHARM GmbH, Yuhan, Histogen", "summary": "The global Degenerative Disc Disease (DDD) market is projected to experience substantial growth, increasing from approximately USD 1.2 billion in 2025 to nearly USD 7.2 billion by 2036, with a CAGR of 19.04%. This expansion is attributed to advancements in regenerative therapies,", "url": "https://www.barchart.com/story/news/3206658/degenerative-disc-disease-market-statistics-expected-to-experience-major-growth-by-2036-according-to-delveinsight-mesoblast-discgenics-biosplice-therapeutics-biopharm-gmbh-yuhan-histogen", "source_name": "Barchart.com", "published_at": "2026-07-10T07:42:08", "published_display": "10 Jul 2026 07:42", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (MESO) CFO awarded 650,000 options at A$2.90 strike, expiring 2032", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPZ0JLNEx4OGRnM1NPbFRGMkxvMWEydk5QQ0JCNmNKd3RrVk5sRWxuNE5Pb0xaaHNQVTNBS2xMejRSZmUtdFJ2RFE4cTNxTkZDZ0NSNXhNUkdQWEtjR21XalRIcThibXBfQ1hhMDBqakRTZVMxMFdtUkYwWnZCellRMHJOQ2NZdVVnNm1zU2RkUURpUEpxazc5OVpSQ1pFVkhnTmJELWd1MklCUWc?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-10T02:10:18+00:00", "published_display": "10 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ryoncil revenue hits US$36M in Q4, FY26 total at US$115M", "summary": "Mesoblast Limited announced strong Ryoncil net revenue, reaching US$36 million in Q4 FY26 and US$115 million for the full fiscal year, exceeding projections due to high U.S. pediatric demand. CEO Dr. Silviu Itescu confirmed the company's robust capital position, fueled by revenue", "url": "https://scanx.trade/stock-market-news/companies/ryoncil-revenue-hits-us-36m-in-q4-fy26-total-at-us-115m/45191341", "source_name": "scanx.trade", "published_at": "2026-07-10T03:10:17", "published_display": "10 Jul 2026 03:10", "sentiment": "positive", "sentiment_pct": 93, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast delivers full year revenue of US$115M", "summary": "Mesoblast (ASX:MSB) reported a full-year net revenue of US$115 million, exceeding initial projections due to strong sales of its approved cellular medicine. The company also recorded US$36 million in net revenue for the fourth quarter and plans to use a new five-year credit facil", "url": "https://grafa.com/en/news/australia/mesoblast-delivers-full-year-revenue-of-us-115m", "source_name": "grafa.com", "published_at": "2026-07-10T01:01:00", "published_display": "10 Jul 2026 01:01", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast Reports Strong RYONCIL\u00ae Revenue, Exceeding Projections", "summary": "Mesoblast Limited (ASX:MSB) announced strong financial results for its product Ryoncil\u00ae, with Q4 net revenue of US$36 million and a full-year net revenue of US$115 million, exceeding initial projections. Ryoncil\u00ae is the first FDA-approved mesenchymal stromal cell product for chil", "url": "https://www.sharecafe.com.au/2026/07/10/mesoblast-reports-strong-ryoncil-revenue-exceeding-projections/", "source_name": "Sharecafe", "published_at": "2026-07-10T00:10:17", "published_display": "10 Jul 2026 00:10", "sentiment": "positive", "sentiment_pct": 93, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ryoncil\u00ae Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026", "summary": "Mesoblast Limited announced Ryoncil\u00ae (remestemcel-L-rknd) achieved net revenue of US$36 million for the fourth quarter and US$115 million for the full year ended June 30, 2026. The company is pleased with Ryoncil's market uptake since its launch and anticipates continued revenue ", "url": "https://sg.finance.yahoo.com/news/ryoncil-delivers-net-revenue-us-003000076.html", "source_name": "Market source", "published_at": "2026-07-09T20:30:00", "published_display": "09 Jul 2026 20:30", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast Ltd outlook for regenerative medicine. MESO stock aligns long-term strategy", "summary": "Mesoblast Ltd is a biotechnology company focused on developing regenerative cell therapies for serious inflammatory and cardiovascular diseases, with its MESO stock reflecting a long-term investment case in advanced biologics. The company's strategy involves a pipeline of allogen", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/mesoblast-ltd-outlook-for-regenerative-medicine-meso-stock-aligns/69716898", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T19:09:23", "published_display": "07 Jul 2026 19:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Mesoblast (ASX:MSB) Is Up 9.3% After FDA Accepts Modular BLA Review For Rexlemestrocel-L", "summary": "Mesoblast (ASX:MSB) shares rose 9.3% after the FDA accepted a modular Biologics License Application (BLA) review for its drug rexlemestrocel-L. The drug aims to prevent life-threatening gastrointestinal bleeding in end-stage heart failure patients supported by left ventricular as", "url": "https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/why-mesoblast-asxmsb-is-up-93-after-fda-accepts-modular-bla/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-03T17:10:32", "published_display": "03 Jul 2026 17:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bell Potter Maintains MESOBLAST LTD(MEOBF.US) With Buy Rating, Raises Target Price to $3.08", "summary": "Bell Potter has reiterated its Buy rating for MESOBLAST LTD (MEOBF.US) and increased its target price to $3.08. This suggests a continued positive outlook from the analyst firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/72360550/bell-potter-maintains-mesoblast-ltd-meobfus-with-buy-rating-raises", "source_name": "Moomoo", "published_at": "2026-07-02T05:40:27", "published_display": "02 Jul 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Mesoblast (ASX:MSB) Undervalued Following FDA Progress For Rexlemestrocel L?", "summary": "Mesoblast (ASX:MSB) stock is gaining attention after the US FDA accepted its Biologics License Application for rexlemestrocel-L and granted a modular review request for LVAD-related risks, streamlining its approval pathway. Despite recent gains, the stock remains down 26.35% year", "url": "https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-mesoblast-asxmsb-undervalued-following-fda-progress-for-r/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-02T05:40:16", "published_display": "02 Jul 2026 05:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (ASX:MSB) Stock Forecast & Analyst Predictions", "summary": "Mesoblast (ASX:MSB) is forecast to achieve significant earnings and revenue growth, with EPS expected to grow by 72.5% and revenue by 38.4% annually. The company has multiple products in development and commercialization, including Ryoncil (FDA-approved) and Rexlemestrocel-L, tar", "url": "https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/future", "source_name": "Simply Wall Street", "published_at": "2026-07-02T04:10:32", "published_display": "02 Jul 2026 04:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (NASDAQ: MESO) moves rexlemestrocel-L BLA into FDA modular review", "summary": "Mesoblast Limited (NASDAQ: MESO) announced it has received a Biologics License Application (BLA) filing number from the FDA for its cell therapy rexlemestrocel-L. The company has requested a modular review for the therapy, which aims to prevent life-threatening gastrointestinal b", "url": "https://www.stocktitan.net/sec-filings/MESO/6-k-mesoblast-ltd-current-report-foreign-issuer-f37ae55f07e4.html", "source_name": "Stock Titan", "published_at": "2026-07-01T09:39:11", "published_display": "01 Jul 2026 09:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs", "summary": "Mesoblast Limited has received a Biologics License Application (BLA) filing number from the U.S. FDA for rexlemestrocel-L and requested a modular review. This therapy aims to prevent life-threatening gastrointestinal bleeding in end-stage heart failure patients with LVADs, an ind", "url": "https://sg.finance.yahoo.com/news/mesoblast-receives-bla-filing-number-003800419.html", "source_name": "Market source", "published_at": "2026-07-01T03:40:55", "published_display": "01 Jul 2026 03:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Duratec (ASX:DUR), Elsight (ASX:ELS) and Mesoblast (ASX:MSB): Why These Growth Stocks Are Drawing Market Attention", "summary": "Duratec (ASX:DUR), Elsight (ASX:ELS), and Mesoblast (ASX:MSB) are attracting significant market attention due to their expanding growth opportunities, substantial insider ownership, and strong operational execution. These companies operate in diverse sectors including infrastruct", "url": "https://kalkinemedia.com/au/stocks/growth/duratec-asxdur-elsight-asxels-and-mesoblast-asxmsb-why-these-growth-stocks-are-drawing-market-attention", "source_name": "Kalkine Media", "published_at": "2026-07-01T01:09:34", "published_display": "01 Jul 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (MESO) Secures FDA Filing for Rexlemestrocel-L Review", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPTXNqRmM5bW5lRHR0bDl3MWFNYTBBWVR3V1l5VEw2dlBXT09VX0FkZ0JQaW9SNUU2cnJvMUJ2ci1OSkE4UHNfZE4ydDU2d3JLT0JkYWxXQVQyT1FhcE94dGJFMk5UZDJybmFkV0hOMGxCQmlBRkxXSlFBZnVVWXV3Z0Zub1VJUkRIdFFxZE1YcUUyamkwR3RRN2NkN1dBeGpwWVBacDNtNlVnQzBLOWN3SVBhSUFQRGMtZXdEODhqTWtDV3NpVlNOOFRuM3hua1NPRTVfOUtR?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast Accesses $50 Million Credit Line to Refinance Debt Obligations", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/mesoblast-accesses-50-million-credit-083916175.html", "source_name": "MT Newswires", "published_at": "2026-06-25T08:39:16+00:00", "published_display": "25 Jun 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast Limited (MESO), One of the Best Long-Term ASX Stocks To Buy Right Now; See Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQSnM4Q1AzUmFfMkVIQ0xuNW9NY2lVQWwyV0FZc1BueEIyYUN0TzRDOTVHcUFnX2JpVG5oajhaUEVyXzcxRDllWGZGQlEyTmlRa0o0VFhpUklGNUVITjBCamkyZ0RwXzROVmh5bDdKVm8xTWViUXRQaTdfbHEwNndiME04eXFsdnNJa3hkRlhicC1fN3AyZWcyWVJsUmo?oc=5", "source_name": "Market source", "published_at": "2026-04-19T07:00:00+00:00", "published_display": "19 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Mesoblast Limited (MESO) is One of the Best Low Priced Biotech Stocks to Invest in", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNb2REazdfc0JsenFOLVJLMnNyNmx6R0tHU3JqTGlaYnF4LTVvNnNGTjRRYW83UzZqLUFxdG1feVRzQlBfLTRrcEsxS0N6X0lJcnlKaVh1ZFR2TS1yaU41U1AyeExfNnU5YUVDak1aMEUxbFcwcVlZUGhDMkZoVTVkajZyV3RsR25ha0NiU3c5V3VobHNPdGF3WXhGaWxRWjRH?oc=5", "source_name": "Market source", "published_at": "2026-04-19T07:00:00+00:00", "published_display": "19 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gregory George Adds To Mesoblast Position With Multi-Market Share Purchases", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOZ0JKWk93LVJ6YnNrVHY1UThpQktrN2R6X0ZIT2l0Zlo2LVJTcVZfUHYtNjZxVmYxRmtxZkJQcnFmM21XeGwtRjFYLW16QzFmVGxBb00tVzM3RUVtV1ZXeWdCc0NUUnJ2T3JWbmQySi1MMERhTlFOaDJXQ3hITldxM3V1NTlnbHRIc0s2eXdJNnY4RFJjNmt3?oc=5", "source_name": "Market source", "published_at": "2026-04-12T07:00:00+00:00", "published_display": "12 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast says Ryoncil is nearing $100M as new trials move ahead", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQbzZoSFRVQXM3OHUyN2RqSHlMZUlFS2NWRDJ5R2hyT3JTUC1RaEVtVlAxVmprYS1qck5GUlBNWEZwLUNiVWNLT0NJVmFrc1NBOGNaanRSSzJLaWxCb2RvR3hwaTlRdDFKOVltRWE2QjFlbVlKb2hyRGxCTWdiMGw1ckNCRVgyb1B2RmtINlQtRVJJU3lJOWxPdEl5U294ai1xc0g1OWJPNU83azNLQW9PYTNKY0NuVU9HMDY4b19Ucw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Mesoblast (ASX:MSB) Offering Value After Recent Share Price Declines?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast shares are back in the red on Tuesday. Here\u2019s why", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNYlZMMG9CbC1Qei1paGlEaUNnWC1YUFdZeDJ1dG5EMW1sQXBJQllBZkVxaklNZU9mWjVFcXpSYlhlLVRPd3ZxdzNMY3NiNE8yZEVWeHJ3cWNfanZRWDJSWENtNU9lenUwa3JqSUhPdUNIb3J5LXlLdE9ZQ1FCVi10MHA2YTV1X3NFZGd1SzRWZEdrTW1sc2s3UA?oc=5", "source_name": "The Motley Fool Australia", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (ASX:MSB; Nasdaq:MESO) Sets Stage for R&D Day as Ryoncil\u00ae Gains Commercial Traction", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPOWdlbWxiX2dUbXBrRF9YakpoZ1dLX1F0eGFaTjU5LVVPSnVuWkU0cmptcUo2RUE4a1k0dFJfRlVoZ29RYktYRk1OcXpoSHhMbURxQjNuVUdxc2tSZnd3eEVUNGQyY1VlTkhyWDJEM0FzcHlLNVFKWl90MDF6Y004Z19KQWxCcHgwLU5Ob1RxeFZzc0FCRzlxRmVlMWtaV2hROGQyY2h5OHRfalNGVmZOV3cxTnRPc0ZsX0h2TTU5VlBndlN1OUp4Z2RRTmg?oc=5", "source_name": "Kalkine Media", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast to spotlight multi-billion pipeline at April 8 R&D Day", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxPeW1KNnFnV2EzV3RXZThjTGdyVkFMQVVnQzhOY3BRUnktRkR6VFpjY3ZiSUxnSmlnNE1YdVNJQTFCYno0RG9NY3ktMGVNMllEOUZsYXR1dXhHM1NheVZyVkhlYjRjLThGbENaOUxiaXoxVzZrUFJvMXNuQVBOSm11NkdMVk9zVjFRWnFTUUVXMDQwRzJLS2c?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast (ASX:MSB) Is Down 7.1% After Issuing First Ryoncil 2026 Revenue Guidance \u2013 Has The Bull Case Changed?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiekFVX3lxTE56ZjVJaVI3VG9rT1F0SmZvTzZvX2ZLTVpWOFJhN3BvbkVsZEsxNm1oa1lhSHZKWDFWU3kyWEthSzhkbE9UMmZoaGdoY0NkQXZ0WGNqQlNQT3RwYkVUVjJ6cTgtWGpNdHdhTEJOTjVWSVRmLXBQQXQ4OTF3?oc=5", "source_name": "Market source", "published_at": "2026-02-28T08:00:00+00:00", "published_display": "28 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast H1 2026 Loss Of US$94.4 Million Tests Bullish Profitability Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-28T08:00:00+00:00", "published_display": "28 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ryoncil drives Mesoblast (NASDAQ: MESO) H1 FY2026 growth and FY26 guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNV3FXQkpNNHhmdEttbTdZYVhPek45Q25GNUZCNk1NdGYxWjdCdlFuY3hucjZiRGhPSm5EZUV0Z0ZXUldPSGpPeWxhN0Y3UmU0NDBCR3JPWGRBS28zeWRvNXFZcGJ0SEdwMnBDbkVGMUgwX3JYUm1HaGNfNXE3a3hUdG93RTFyc25nSXhqeXpWWGF0MlpqTzBadERNbENIb0dmWm96OTJpb2F3THJRaXc?oc=5", "source_name": "Stock Titan", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast Limited (MESO) Stock Analysis: Exploring A 109.83% Potential Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPNlRqcTlzYTE0OXFvaFcyYVZyUEVqYWFKRXRvUm84Rm8xZ1BXRFhUUjBjWWpVZ1FjekdOZHlKUUxBaXUybHNYMTI3YXJIY1pCcHJTbm9MUV9zTThwekNuOExJcGh5SnBZcjY3TVY2TGg0Z0NnWVlKY1JPdHQxTDR6S2RQT0VBNFBsTmlXX29nLTA1MEhtbVMxV3NMU1E3a3FEdWdmdWpUN1Jkcmt5d2w2Rl9POUxOa3VWMEV0c00yUG1zQQ?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Mesoblast Limited (ASX:MSB) Consensus Forecasts Have Become A Little Darker Since Its Latest Report", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-01T07:00:00+00:00", "published_display": "01 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insiders were the key beneficiaries as Mesoblast Limited's (ASX:MSB) market cap rises to AU$3.0b", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-20T07:00:00+00:00", "published_display": "20 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 101, "total_relevant": 59, "sentiment_summary": {"positive": 30, "negative": 2, "neutral": 27, "score": 63, "total": 59, "label": "Constructive news tone", "tone": "positive"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 16.3, "count": 29}, {"event": "earnings", "label": "Earnings", "weight": 9.35, "count": 19}, {"event": "analyst", "label": "Analyst action", "weight": 3.85, "count": 7}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 30, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 15.44, "latest_week": "2026-07-10", "one_week_move": 7.4, "four_week_move": 10.8, "twelve_week_move": -6.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.034302, "market_dynamics_buy_signal": false, "relative_strength": -17.802955, "fair_value_gap": 46.7, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 51.2609, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+7.4% over one week, +10.8% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "News confirmed by price", "tone": "positive", "classification": "confirmed_positive", "summary": "Constructive news tone is being confirmed by positive weekly price action.", "confidence": 73, "badges": ["Sentiment-trend disagreement", "Positive but stretched"], "opportunities": [], "risks": ["Positive news is arriving while the Sharemaestro trend signal is inactive.", "Constructive tone is arriving with price materially above fair value."], "event_label": "Market update", "sentiment_word": "constructive"}, "charts": {"sources": [{"label": "Market source", "count": 14}, {"label": "Stock Titan", "count": 9}, {"label": "simplywall.st", "count": 7}, {"label": "grafa.com", "count": 4}, {"label": "MT Newswires", "count": 3}, {"label": "GuruFocus", "count": 3}, {"label": "Kalkine Media", "count": 3}, {"label": "Simply Wall Street", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 51}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 29}, {"label": "Earnings", "count": 19}, {"label": "Analyst action", "count": 7}, {"label": "Guidance", "count": 2}, {"label": "Regulatory and legal", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "63/100", "tone": "positive", "text": "Constructive news tone"}, {"label": "Market reaction", "value": "News confirmed by price", "tone": "positive", "text": "Constructive news tone is being confirmed by positive weekly price action."}, {"label": "Primary event", "value": "Market update", "tone": "positive", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "51", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+7.4% over one week, +10.8% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Mesoblast Limited (MESO) is a Great Momentum Stock: Should You Buy?"}], "updated_at": "2026-07-18T04:47:28.894772+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}